379 related articles for article (PubMed ID: 24244833)
21. Triple negative breast cancer: looking for the missing link between biology and treatments.
Palma G; Frasci G; Chirico A; Esposito E; Siani C; Saturnino C; Arra C; Ciliberto G; Giordano A; D'Aiuto M
Oncotarget; 2015 Sep; 6(29):26560-74. PubMed ID: 26387133
[TBL] [Abstract][Full Text] [Related]
22.
Uzelac B; Krivokuca A; Susnjar S; Milovanovic Z; Supic G
Genet Test Mol Biomarkers; 2021 Mar; 25(3):227-235. PubMed ID: 33734898
[No Abstract] [Full Text] [Related]
23. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
24. A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer.
Jain V; Kumar H; Anod HV; Chand P; Gupta NV; Dey S; Kesharwani SS
J Control Release; 2020 Oct; 326():628-647. PubMed ID: 32653502
[TBL] [Abstract][Full Text] [Related]
25. HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients.
Bae SY; La Choi Y; Kim S; Kim M; Kim J; Jung SP; Choi MY; Lee SK; Kil WH; Lee JE; Nam SJ
Breast Cancer Res Treat; 2013 Jun; 139(3):741-50. PubMed ID: 23722313
[TBL] [Abstract][Full Text] [Related]
26. Triple Negative Breast Cancer - An Overview.
Aysola K; Desai A; Welch C; Xu J; Qin Y; Reddy V; Matthews R; Owens C; Okoli J; Beech DJ; Piyathilake CJ; Reddy SP; Rao VN
Hereditary Genet; 2013; 2013(Suppl 2):. PubMed ID: 25285241
[TBL] [Abstract][Full Text] [Related]
27. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.
Chang HR; Glaspy J; Allison MA; Kass FC; Elashoff R; Chung DU; Gornbein J
Cancer; 2010 Sep; 116(18):4227-37. PubMed ID: 20549829
[TBL] [Abstract][Full Text] [Related]
28. No association between triple-negative breast cancer and prognosis of patients receiving breast-conserving treatment.
Mu L; Liu Y; Xiao M; Liu W; Liu M; Wang X
Oncol Lett; 2017 Dec; 14(6):7862-7872. PubMed ID: 29250179
[TBL] [Abstract][Full Text] [Related]
29. Search for novel therapies for triple negative breast cancers (TNBC): analogs of luteinizing hormone-releasing hormone (LHRH) and growth hormone-releasing hormone (GHRH).
Buchholz S; Seitz S; Engel JB; Montero A; Ortmann O; Perez R; Block NL; Schally AV
Horm Mol Biol Clin Investig; 2012 Apr; 9(1):87-94. PubMed ID: 25961354
[TBL] [Abstract][Full Text] [Related]
30. Triple-Negative Breast Cancer: The Progress of Targeted Therapies and Future Tendencies.
Damaskos C; Garmpi A; Nikolettos K; Vavourakis M; Diamantis E; Patsouras A; Farmaki P; Nonni A; Dimitroulis D; Mantas D; Antoniou EA; Nikolettos N; Kontzoglou K; Garmpis N
Anticancer Res; 2019 Oct; 39(10):5285-5296. PubMed ID: 31570423
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy.
Yang R; Li Y; Wang H; Qin T; Yin X; Ma X
Mol Biomed; 2022 Mar; 3(1):8. PubMed ID: 35243562
[TBL] [Abstract][Full Text] [Related]
32. Novel chimeric antigen receptor T cell-based immunotherapy: a perspective for triple-negative breast cancer.
Geng P; Chi Y; Yuan Y; Yang M; Zhao X; Liu Z; Liu G; Liu Y; Zhu L; Wang S
Front Cell Dev Biol; 2023; 11():1158539. PubMed ID: 37457288
[TBL] [Abstract][Full Text] [Related]
33. Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients.
Agelaki S; Dragolia M; Markonanolaki H; Alkahtani S; Stournaras C; Georgoulias V; Kallergi G
Oncotarget; 2017 Jan; 8(3):5309-5322. PubMed ID: 28029660
[TBL] [Abstract][Full Text] [Related]
34. Triple-negative breast cancer: A run-through of features, classification and current therapies.
Manjunath M; Choudhary B
Oncol Lett; 2021 Jul; 22(1):512. PubMed ID: 33986872
[TBL] [Abstract][Full Text] [Related]
35. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
[TBL] [Abstract][Full Text] [Related]
36. Novel therapeutic strategies in the treatment of triple-negative breast cancer.
Oualla K; El-Zawahry HM; Arun B; Reuben JM; Woodward WA; Gamal El-Din H; Lim B; Mellas N; Ueno NT; Fouad TM
Ther Adv Med Oncol; 2017 Jul; 9(7):493-511. PubMed ID: 28717401
[TBL] [Abstract][Full Text] [Related]
37. Folate Receptor Alpha Immunohistochemistry in Cytology Specimens of Metastatic Breast Carcinoma.
Sheikh UN; Cohen C; Siddiqui MT
Acta Cytol; 2015; 59(4):298-304. PubMed ID: 26413911
[TBL] [Abstract][Full Text] [Related]
38. Narrowing the focus: Therapeutic cell surface targets for refractory triple-negative breast cancer.
Tafreshi NK; Morse DL; Lee MC
World J Clin Oncol; 2020 Apr; 11(4):169-179. PubMed ID: 32355639
[TBL] [Abstract][Full Text] [Related]
39. Triple negative breast cancer: unmet medical needs.
Pal SK; Childs BH; Pegram M
Breast Cancer Res Treat; 2011 Feb; 125(3):627-36. PubMed ID: 21161370
[TBL] [Abstract][Full Text] [Related]
40. Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer.
Shi J; Liu F; Song Y
Cancer Manag Res; 2020; 12():9375-9387. PubMed ID: 33061626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]